Dr. Lynch is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-520-5000
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1989 - 1991
- Massachusetts General HospitalResidency, Internal Medicine, 1986 - 1989
- Yale School of MedicineClass of 1986
Certifications & Licensure
- WA State Medical License 2021 - 2025
- MA State Medical License 1988 - 2022
- CT State Medical License 2009 - 2015
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 6 citationsMultiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistanceS. Inder, Mark Bates, N. Ni Labhrai, Niamh McDermott, Julia Schneider
Scientific Reports. 2019-11-22 - 20 citationsAre all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.Eva M. Bolton, Thomas J. Lynch
BJU International. 2018-09-01 - 26 citationsErratum: Submucosal Gland Myoepithelial Cells Are Reserve Stem Cells That Can Regenerate Mouse Tracheal Epithelium (Cell Stem Cell (2018) 22(5) (653–667.e5) (S19345909...Thomas J. Lynch, Preston J. Anderson, Pavana G. Rotti, Scott R. Tyler, Adrianne K. Crooke
Cell Stem Cell. 2018-05-03
Press Mentions
- Meet the Leaders of the Best Healthcare Employers for Women: ForbesJuly 25th, 2024
- Transformative $78M Gift to Establish New Precision Oncology InstituteSeptember 8th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: